Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chiome Bioscience's Other Operating Expense for the
three
months ended in Dec. 2025 was 円135.5 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was 円555.8 Mil.
Chiome Bioscience's quarterly Other Operating Expense
increased
from Jun. 2025 (円138.4 Mil) to Sep. 2025 (円143.5 Mil) but then
declined
from Sep. 2025 (円143.5 Mil) to Dec. 2025 (円135.5 Mil).
Chiome Bioscience's annual Other Operating Expense
declined
from Dec. 2023 (円551.9 Mil) to Dec. 2024 (円527.0 Mil) but then
increased
from Dec. 2024 (円527.0 Mil) to Dec. 2025 (円558.8 Mil).
Chiome Bioscience Other Operating Expense Related Terms
Chiome Bioscience Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Chiome Bioscience's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円555.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of 円555.8 Mil mean?
Chiome Bioscience (TSE:4583) has a Other Operating Expense of 円555.8 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Chiome Bioscience and its competitors.
Is Chiome Bioscience's Other Operating Expense too high?
Chiome Bioscience's current Other Operating Expense is 円555.8 Mil. Overall, Chiome Bioscience has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Other Operating Expense compare to VRTX and REGN?
Chiome Bioscience's Other Operating Expense of 円555.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Chiome Bioscience and its competitors. Chiome Bioscience's current Other Operating Expense is 円555.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Modestly Undervalued. The stock's GF Value™ is 円83.81, compared to a current price of 円75.00 — trading 10.5% below its estimated fair value. The current Other Operating Expense is 円555.8 Mil. Chiome Bioscience's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Other Operating Expense is 円555.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chiome Bioscience (TSE:4583) Overvalued in 2026?
Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued.
The current stock price of 円75.00 is trading 10.5% below its estimated GF Value™ of 円83.81.
GuruFocus considers Chiome Bioscience to be Modestly Undervalued.
Key valuation signals for TSE:4583:
Other Operating Expense: 円555.8 Mil
GF Value™: 円83.81 vs. price of 円75.00 (10.5% below fair value)
No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
52GF Score
Get the complete analysis for TSE:4583
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4583 has been successfully added to your 
